Results 1 to 10 of about 92,880 (144)
In silico prediction of mutant HIV-1 proteases cleaving a target sequence. [PDF]
PLoS ONE, 2014 HIV-1 protease represents an appealing system for directed enzyme re-design, since it has various different endogenous targets, a relatively simple structure and it is well studied. Recently Chaudhury and Gray (Structure (2009) 17: 1636-1648) published a
Jan H Jensen +3 more
doaj +7 more sources
HIV Protease: Historical Perspective and Current Research
Viruses, 2021 The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Robert W Harrison, Irène T Weber
exaly +3 more sources
A folding inhibitor of the HIV-1 Protease [PDF]
Proteins: Structure, Function, and Bioinformatics, 2005 Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single domain proteins, like each of the monomers forming the HIV-1-PR homodimer, is controlled by local elementary ...
Abkevich +35 more
core +4 more sources
Molecular Basis for Drug Resistance in HIV-1 Protease
Viruses, 2010 HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Akbar Ali, Yufeng Cai, Aysegul Özen
exaly +3 more sources
Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. [PDF]
PLoS Pathogens, 2010 In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit ...
Sekar Natesampillai +6 more
doaj +1 more source
HIV protease inhibitors and obesity [PDF]
Current Opinion in Endocrinology, Diabetes and Obesity, 2010 To review the current scientific literature and recent clinical trials on HIV protease inhibitors and their potential role in the pathogenesis of lipodystrophy and metabolic disorders.HIV protease inhibitor treatment may affect the normal stimulatory effect of insulin on glucose and fat storage.
Erdembileg, Anuurad +2 more
openaire +2 more sources
Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. [PDF]
PLoS ONE, 2008 Acute HIV-1 infection of CD4 T cells often results in apoptotic death of infected cells, yet it is unclear what evolutionary advantage this offers to HIV-1.
Gary D Bren +6 more
doaj +1 more source
Predicting HIV-1 Protease Cleavage Sites With Positive-Unlabeled Learning
Frontiers in Genetics, 2021 Understanding the substrate specificity of HIV-1 protease plays an essential role in the prevention of HIV infection. A variety of computational models have thus been developed to predict substrate sites that are cleaved by HIV-1 protease, but most of ...
Zhenfeng Li +3 more
doaj +1 more source
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. [PDF]
PLoS ONE, 2010 HIV protease inhibitors must penetrate into cells to exert their action. Differences in the intracellular pharmacokinetics of these drugs may explain why some patients fail on therapy or suffer from drug toxicity.
Jeroen J A van Kampen +10 more
doaj +1 more source
Rapid enzymatic test for phenotypic HIV protease drug resistance [PDF]
, 2003 A phenotypic resistance test based on recombinant expression of the active HIV protease in E. coli from patient blood samples was developed. The protease is purified in a rapid onestep procedure as active enzyme and tested for inhibition by five selected
Assfalg-Machleidt, Irmgard +5 more
core +1 more source